<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29124963</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>09</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>09</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1549-7801</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>38</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>Critical reviews in biotechnology</Title>
          <ISOAbbreviation>Crit Rev Biotechnol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Relevance and bio-catalytic strategies for the kinetic resolution of ketoprofen towards dexketoprofen.</ArticleTitle>
        <Pagination>
          <StartPage>778</StartPage>
          <EndPage>800</EndPage>
          <MedlinePgn>778-800</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/07388551.2017.1399249</ELocationID>
        <Abstract>
          <AbstractText>This review presents the most relevant investigations concerning the biocatalytic kinetic resolution of racemic ketoprofen to dexketoprofen for the last 22 years. The advantages related to the administration of the dex-enantiomer in terms of human health, the so called "chiral switch" in the pharmaceutical industry and the sustainability of biotransformations have been the driving forces to develop innovative technology to obtain dexketoprofen. In particular, the kinetic resolution of racemic ketoprofen through enantiomeric esterification and hydrolysis using lipases as biocatalysts are thoroughly revised and commented upon. In this context, the biocatalysts, acyl-acceptors (alcohols), reaction conditions, conversion, enantiomeric excess, and enantiomeric ratio among others are discussed. Moreover, the investigations concerning scaling up processes in order to obtain an optically pure enantiomer of the profen are presented. Finally, some guidelines about perspectives of the technology and research opportunities are given.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Toledo</LastName>
            <ForeName>María Victoria</ForeName>
            <Initials>MV</Initials>
            <AffiliationInfo>
              <Affiliation>a Centro de Investigación y Desarrollo en Ciencias Aplicadas-Dr. Jorge J. Ronco (CINDECA) , Universidad Nacional de La Plata, CONICET , La Plata , Buenos Aires , Argentina.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Briand</LastName>
            <ForeName>Laura Estefanía</ForeName>
            <Initials>LE</Initials>
            <AffiliationInfo>
              <Affiliation>a Centro de Investigación y Desarrollo en Ciencias Aplicadas-Dr. Jorge J. Ronco (CINDECA) , Universidad Nacional de La Plata, CONICET , La Plata , Buenos Aires , Argentina.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Crit Rev Biotechnol</MedlineTA>
        <NlmUniqueID>8505177</NlmUniqueID>
        <ISSNLinking>0738-8551</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>023C2WHX2V</RegistryNumber>
          <NameOfSubstance UI="D014325">Tromethamine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>90Y4QC304K</RegistryNumber>
          <NameOfSubstance UI="D007660">Ketoprofen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.1.3</RegistryNumber>
          <NameOfSubstance UI="D008049">Lipase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>N674F7L21E</RegistryNumber>
          <NameOfSubstance UI="C118296">dexketoprofen trometamol</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D055162" MajorTopicYN="N">Biocatalysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002626" MajorTopicYN="N">Chemistry, Pharmaceutical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004951" MajorTopicYN="N">Esterification</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006868" MajorTopicYN="N">Hydrolysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007660" MajorTopicYN="N">Ketoprofen</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008049" MajorTopicYN="N">Lipase</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013237" MajorTopicYN="N">Stereoisomerism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014325" MajorTopicYN="Y">Tromethamine</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Ketoprofen</Keyword>
        <Keyword MajorTopicYN="N">biocatalysis</Keyword>
        <Keyword MajorTopicYN="N">dexketoprofen</Keyword>
        <Keyword MajorTopicYN="N">esterification</Keyword>
        <Keyword MajorTopicYN="N">hydrolysis</Keyword>
        <Keyword MajorTopicYN="N">kinetic resolution</Keyword>
        <Keyword MajorTopicYN="N">lipases</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>9</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29124963</ArticleId>
        <ArticleId IdType="doi">10.1080/07388551.2017.1399249</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
